1
Andreas G Weichert
Andreas Weichert, Joachim Brendel, Heinz Werner Kleemann, Hans Jochen Lang, Jan Robert Schwark, Wolfgang Scholz, Udo Albus: 4-fluoroalkyl-substituted benzoylguanidines, process for their preparation, their use as a medicament or diagnostic, and medicament containing them. Aventis Pharma Deutschland, Finnegan Henderson Farabow Garrett & Dunner L, December 5, 2000: US06156800 (4 worldwide citation)

There are described benzoylguanidines of the formula I ##STR1## where R(1) is R(4)--SO.sub.m, R(5)R(6)N--SO.sub.2 --; O.sub.p --(CH.sub.2).sub.q --(CF.sub.2).sub.r --CF.sub.3 ; --SR(10), --OR(10) or --CR(10)R(11)R(12); R(2) is --(CH.sub.2).sub.u --(CF.sub.2).sub.t --CF.sub.3 ; R(3) is hydrogen or in ...


2

3
Richard James Bastin, Bruce Hamilton Lithgow: Abuse resistant tablets. Aventis Pharma, Ross J Oehler, George G Wang, October 30, 2001: US06309668 (190 worldwide citation)

This invention relates to an abuse resistant tablet containing two or more layers having one or more drugs and one or more gelling agents and its preparation. The drug(s) and gelling agent(s) are in separate layers of the tablet. The multilayer tablet is particularly suitable for the administration ...


4
Thierry Verrecchia: Stabilized nanoparticles which are filterable under sterile conditions. Aventis Pharma, Christine M Hansen, Irving Newman, Ross Oehler, October 31, 2000: US06139870 (87 worldwide citation)

Stabilized nanoparticles capable of being filtered under sterile conditions and including at least one hydrophobic, water-insoluble and non-water-dispersible polymer or copolymer (and optionally an active principle) emulsified in a solution of phospholipids and an oleic acid salt.


5
Gary A Flynn, Barbara A Anderson, Manfred Gerken, Bernd Jablonka, Heinz Werner Kleemann, Wolfgang Linz, Werner Seiz, Bernhard Seuring: Mercaptoacetylamide derivatives, a process for their preparation and their use. Aventis Pharma Deutschland, Lawrence L Martin, Balaram Gupta, August 5, 2003: US06602866 (75 worldwide citation)

This invention discloses and claims a series of mercaptoacetylamide derivatives of formula I. Also disclosed and claimed are pharmaceutical compositions incorporating these compounds and processes for preparing said compounds. The use of said compounds for inhibition of the enzymes angiotensin conve ...


6
Johann Ertl, Paul Habermann, Karl Geisen, Gerhard Seipke: Insulin derivatives having a rapid onset of action. Aventis Pharma Deutschland, Finnegan Henderson Farabow Garrett & Dunner L, April 24, 2001: US06221633 (73 worldwide citation)

The present invention relates to insulin derivatives which in comparison to human insulin, have an accelerated onset of action, to a process for their preparation and to their use, in particular in pharmaceutical preparations for the treatment of diabetes mellitus. In particular, the present inventi ...


7

8
Wolf R Achterrath: Method for treating cancer using camptothecin derivatives and 5-fluorouracil. Aventis Pharma, Finnegan Henderson Farabow Garrett & Dunner, June 11, 2002: US06403569 (57 worldwide citation)

A combination therapy for treating cancer including administering at least one camptothecin derivative in conjunction with another anticancer agent. The combination therapy is preferably used as a first-line therapy for treating metastatic colorectal cancer and preferably involves administration of ...


9

10
Nazare Marc Dr, Will David William Dr, Peyman Anuschirwan Dr, Matter Hans Dr, Zoller Gerhard Dr, Gerlach Uwe Dr: Inhibitors of factor xa and factor viia. Aventis Pharma, June 26, 2002: EP1217000-A1 (54 worldwide citation)

The present invention relates to compounds of the formula I, R-Q-X-Q'-W-U-V-G-M in which Q; X; Q', U, V, G and M have the meanings indicated in the claims; R is aryl or heteroaryl; and W is selected from aryl, heteroaryl, carbocyclic and heterocyclic groups. The compounds of the formula I are valuab ...